You are about to leave jnjmedicaldevices.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
Powering Transformations! Over the last 20 years, Ethicon has contributed more to advancing bariatric surgery and the science and treatment of obesity than any other device maker.
The most trusted brand in bariatric surgery
Innovation in the operating room. Ethicon offers a comprehensive portfolio of medical device products for bariatric and metabolic surgery. We relentlessly invest in innovation to provide a comprehensive portfolio of market-leading products.
Ethicon Bariatric Resources
Ethicon provides a comprehensive portfolio of materials designed to power transformations by supporting your engagements with healthcare professionals and patients at every stage of their journey, from making the decision to have surgery, to sustaining a healthy lifestyle post-operatively.
Bariatric Professional Education Courses
The Johnson & Johnson Institute offers comprehensive Bariatric specialty learning opportunities on the safe and effective usage of Ethicon devices, surgical techniques and tips and tricks on enhancing the patient experience and outcomes.
Access & Reimbursement
Expanding coverage for millions of Americans by helping patients with obesity gain and maintain access to the life-changing treatment they deserve. Materials to assist in talking to payers and employers about covering Bariatric surgery.
Featured Bariatric Products
ECHELON FLEX™ GST System
Bariatric surgeons prefer Ethicon endocutters more often than Medtronic endocutters.† Controls tissue movement to enable you to transect as you intend even in challenging tissue.‡
HARMONIC® HD 1000i Shears
Harmonic® HD 1000i Shears are designed to enable surgical efficiency through precise energy delivery, fine dissection and strong vessel sealing.
STRATAFIX™ Spiral Knotless Tissue Control Device
With more points of fixation than traditional sutures. STRATAFIX™ Devices provide more consistent tension control over every pass and provides more security and strength than interrupted suture closure with more efficiency than continuous closure.1-3
EVICEL® Fibrin Sealant (Human)
EVICEL Fibrin Sealant provides sustained hemostasis, demonstrated in high-risk patients,4 with effective clot formation regardless of patient coagulation profile.4,5
As potential patients learn about bariatric and metabolic surgery, they also search for surgeons in their area.
Your Choice of Stapler Matters
With decisions from surgical approach to post-operative management, every choice matters. We focus on providing you powered staplers that help improve patient outcomes, with results backed by clinical evidence
Research & Evidence
Driving the body of evidence that shows bariatric surgery is the most effective and durable treatment for severe obesity.
HealthPartner supports your patients through their bariatric surgery journey by guiding them through the pre-surgical process, supporting them in goal setting and allowing them to track their progress
* For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.
† In a 2015 U.S. market research study by Ethicon that surveyed surgeon preference (63.9% Ethicon vs. 24.7% Medtronic) (p<0.001).
‡ Challenging tissue - thick, fragile, and varying thickness and density
1. Vakil JJ, O'Reilly MP, Sutter EG, Mears SC, Belkoff SM, Khanuja HS. Knee arthrotomy repair with a continuous barbed suture: a biomechanical study. J Arthroplasty. 2011;26(5):710-713.
2. Eickmann T, Quane E. Total knee arthroplasty closure with barbed sutures. J Knee Surg. 2010;23(3):163-167.
3. 100326296: Time Zero Tissue Holding - Competitive Claims Comparisons for STRATAFIX™ Knotless Tissue Control Devices vs Various Products. 2015.
4. Chalmers RT, Darling RC III, Wingard JT, et al. Randomized clinical trial of tranexamic acid-free fibrin sealant during vascular surgical procedures. Br J Surg. 2010;97(12):1784–1789.
5. STAR ASA coverage area test using corium tissue on a 45 degree tilted plane. September 2014. Ethicon, Inc.
EVICEL® Fibrin Sealant (Human) Important Safety Information
EVICEL® Fibrin Sealant (Human) is indicated as an adjunct to hemostasis for use in patients undergoing surgery, when control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical.
-Do not inject directly into the circulatory system. Intravascular application of EVICEL® may result in life-threatening thromboembolic events.
-Do not use in individuals known to have anaphylactic or severe systemic reaction to human blood products.
-Do not use for the treatment of severe or brisk arterial bleeding.
-Do not use EVICEL® for spraying in endoscopic or laparoscopic procedures where the minimum recommended distance from the applicator tip to the target site cannot be ensured.
Warnings and Precautions
-Life-threatening air or gas embolism has occurred with the use of spray devices employing a pressure regulator to administer EVICEL®. This event appears to be related to the use of the spray device at pressures higher than recommended and/or at distances closer than recommended to the surface of the tissue.
-Monitor changes in blood pressure, pulse, oxygen saturation, and end-tidal CO2 when spraying EVICEL® because of the possibility of gas embolism.
-To reduce the risk of potentially life-threatening gas embolism, spray EVICEL® using only pressurized CO2 gas at the pressures and distances recommended for the specific tips.
-Use EVICEL® spray application only if it is possible to accurately judge the spray distance, especially during endoscopic or laparoscopic procedures.
-Prior to applying EVICEL®, dry surface areas of the wound by standard techniques (e.g. intermittent application of compresses, swabs, use of suction devices). Prepare and administer EVICEL® according to the instructions and with only devices recommended for this product.
-May carry a risk of transmitting infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
The most common adverse reactions reported in clinical trials are peripheral edema, abdominal abscess, infection, hematoma, incision site hemorrhage, vascular graft occlusion, postoperative wound complication and decreased hemoglobin.
For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.